The outlook for full year 2025 remains unchanged at flat to 1% currency-neutral revenue growth, consistent with the Q2 update. Margins guidance is also unchanged. Q3 reported a slight revenue and ...
Bio-Rad Laboratories, Inc. (BIO) is scheduled to announce Q3 earnings results on Wednesday, October 29th, after market close. The consensus EPS Estimate is $1.9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback